Acceleration of leukocytes' epigenetic age as an early tumorand sex-specific marker of breast and colorectal cancer

Danielle Fernandes Durso, Maria Giulia Bacalini, Claudia Sala, Chiara Pirazzini, Elena Marasco, Massimiliano Bonafé, Ítalo Faria do Valle, Davide Gentilini, Gastone Castellani, Ana Maria Caetano Faria, Claudio Franceschi, Paolo Garagnani, Christine Nardini

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Changes in blood epigenetic age have been associated with several pathological conditions and have recently been described to anticipate cancer development. In this work, we analyze a publicly available leukocytes methylation dataset to evaluate the relation between DNA methylation age and the prospective development of specific types of cancer. We calculated DNA methylation age acceleration using five state-ofthe- art estimators (three multi-site: Horvath, Hannum, Weidner; and two CpG specific: ELOV2 and FHL2) in a cohort including 845 subjects from the EPIC-Italy project and we compared 424 samples that remained cancer-free over the approximately ten years of follow-up with 235 and 166 subjects who developed breast and colorectal cancer, respectively. We show that the epigenetic age estimated from blood DNA methylation data is statistically significantly associated to future breast and male colorectal cancer development. These results are corroborated by survival analysis that shows significant association between age acceleration and cancer incidence suggesting that the chance of developing age-related diseases may be predicted by circulating epigenetic markers, with a dependence upon tumor type, sex and age estimator. These are encouraging results towards the non-invasive and perspective usage of epigenetic biomarkers.

Original languageEnglish
Pages (from-to)23237-23245
Number of pages9
JournalOncotarget
Volume8
Issue number14
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Epigenomics
Colorectal Neoplasms
Leukocytes
Breast Neoplasms
DNA Methylation
Neoplasms
Survival Analysis
Art
Methylation
Italy
Breast
Biomarkers
Incidence

Keywords

  • Cancer, blood
  • ELOVL2
  • Epigenetic clock
  • FHL2

ASJC Scopus subject areas

  • Oncology

Cite this

Durso, D. F., Bacalini, M. G., Sala, C., Pirazzini, C., Marasco, E., Bonafé, M., ... Nardini, C. (2017). Acceleration of leukocytes' epigenetic age as an early tumorand sex-specific marker of breast and colorectal cancer. Oncotarget, 8(14), 23237-23245. https://doi.org/10.18632/oncotarget.15573

Acceleration of leukocytes' epigenetic age as an early tumorand sex-specific marker of breast and colorectal cancer. / Durso, Danielle Fernandes; Bacalini, Maria Giulia; Sala, Claudia; Pirazzini, Chiara; Marasco, Elena; Bonafé, Massimiliano; do Valle, Ítalo Faria; Gentilini, Davide; Castellani, Gastone; Faria, Ana Maria Caetano; Franceschi, Claudio; Garagnani, Paolo; Nardini, Christine.

In: Oncotarget, Vol. 8, No. 14, 01.01.2017, p. 23237-23245.

Research output: Contribution to journalArticle

Durso, DF, Bacalini, MG, Sala, C, Pirazzini, C, Marasco, E, Bonafé, M, do Valle, ÍF, Gentilini, D, Castellani, G, Faria, AMC, Franceschi, C, Garagnani, P & Nardini, C 2017, 'Acceleration of leukocytes' epigenetic age as an early tumorand sex-specific marker of breast and colorectal cancer', Oncotarget, vol. 8, no. 14, pp. 23237-23245. https://doi.org/10.18632/oncotarget.15573
Durso, Danielle Fernandes ; Bacalini, Maria Giulia ; Sala, Claudia ; Pirazzini, Chiara ; Marasco, Elena ; Bonafé, Massimiliano ; do Valle, Ítalo Faria ; Gentilini, Davide ; Castellani, Gastone ; Faria, Ana Maria Caetano ; Franceschi, Claudio ; Garagnani, Paolo ; Nardini, Christine. / Acceleration of leukocytes' epigenetic age as an early tumorand sex-specific marker of breast and colorectal cancer. In: Oncotarget. 2017 ; Vol. 8, No. 14. pp. 23237-23245.
@article{2bdd8a5ee8844b26a7788ad0072efab1,
title = "Acceleration of leukocytes' epigenetic age as an early tumorand sex-specific marker of breast and colorectal cancer",
abstract = "Changes in blood epigenetic age have been associated with several pathological conditions and have recently been described to anticipate cancer development. In this work, we analyze a publicly available leukocytes methylation dataset to evaluate the relation between DNA methylation age and the prospective development of specific types of cancer. We calculated DNA methylation age acceleration using five state-ofthe- art estimators (three multi-site: Horvath, Hannum, Weidner; and two CpG specific: ELOV2 and FHL2) in a cohort including 845 subjects from the EPIC-Italy project and we compared 424 samples that remained cancer-free over the approximately ten years of follow-up with 235 and 166 subjects who developed breast and colorectal cancer, respectively. We show that the epigenetic age estimated from blood DNA methylation data is statistically significantly associated to future breast and male colorectal cancer development. These results are corroborated by survival analysis that shows significant association between age acceleration and cancer incidence suggesting that the chance of developing age-related diseases may be predicted by circulating epigenetic markers, with a dependence upon tumor type, sex and age estimator. These are encouraging results towards the non-invasive and perspective usage of epigenetic biomarkers.",
keywords = "Cancer, blood, ELOVL2, Epigenetic clock, FHL2",
author = "Durso, {Danielle Fernandes} and Bacalini, {Maria Giulia} and Claudia Sala and Chiara Pirazzini and Elena Marasco and Massimiliano Bonaf{\'e} and {do Valle}, {{\'I}talo Faria} and Davide Gentilini and Gastone Castellani and Faria, {Ana Maria Caetano} and Claudio Franceschi and Paolo Garagnani and Christine Nardini",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.15573",
language = "English",
volume = "8",
pages = "23237--23245",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "14",

}

TY - JOUR

T1 - Acceleration of leukocytes' epigenetic age as an early tumorand sex-specific marker of breast and colorectal cancer

AU - Durso, Danielle Fernandes

AU - Bacalini, Maria Giulia

AU - Sala, Claudia

AU - Pirazzini, Chiara

AU - Marasco, Elena

AU - Bonafé, Massimiliano

AU - do Valle, Ítalo Faria

AU - Gentilini, Davide

AU - Castellani, Gastone

AU - Faria, Ana Maria Caetano

AU - Franceschi, Claudio

AU - Garagnani, Paolo

AU - Nardini, Christine

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Changes in blood epigenetic age have been associated with several pathological conditions and have recently been described to anticipate cancer development. In this work, we analyze a publicly available leukocytes methylation dataset to evaluate the relation between DNA methylation age and the prospective development of specific types of cancer. We calculated DNA methylation age acceleration using five state-ofthe- art estimators (three multi-site: Horvath, Hannum, Weidner; and two CpG specific: ELOV2 and FHL2) in a cohort including 845 subjects from the EPIC-Italy project and we compared 424 samples that remained cancer-free over the approximately ten years of follow-up with 235 and 166 subjects who developed breast and colorectal cancer, respectively. We show that the epigenetic age estimated from blood DNA methylation data is statistically significantly associated to future breast and male colorectal cancer development. These results are corroborated by survival analysis that shows significant association between age acceleration and cancer incidence suggesting that the chance of developing age-related diseases may be predicted by circulating epigenetic markers, with a dependence upon tumor type, sex and age estimator. These are encouraging results towards the non-invasive and perspective usage of epigenetic biomarkers.

AB - Changes in blood epigenetic age have been associated with several pathological conditions and have recently been described to anticipate cancer development. In this work, we analyze a publicly available leukocytes methylation dataset to evaluate the relation between DNA methylation age and the prospective development of specific types of cancer. We calculated DNA methylation age acceleration using five state-ofthe- art estimators (three multi-site: Horvath, Hannum, Weidner; and two CpG specific: ELOV2 and FHL2) in a cohort including 845 subjects from the EPIC-Italy project and we compared 424 samples that remained cancer-free over the approximately ten years of follow-up with 235 and 166 subjects who developed breast and colorectal cancer, respectively. We show that the epigenetic age estimated from blood DNA methylation data is statistically significantly associated to future breast and male colorectal cancer development. These results are corroborated by survival analysis that shows significant association between age acceleration and cancer incidence suggesting that the chance of developing age-related diseases may be predicted by circulating epigenetic markers, with a dependence upon tumor type, sex and age estimator. These are encouraging results towards the non-invasive and perspective usage of epigenetic biomarkers.

KW - Cancer, blood

KW - ELOVL2

KW - Epigenetic clock

KW - FHL2

UR - http://www.scopus.com/inward/record.url?scp=85017017223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017017223&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.15573

DO - 10.18632/oncotarget.15573

M3 - Article

VL - 8

SP - 23237

EP - 23245

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 14

ER -